Evaluation of efficacy and toxicity of neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and paclitaxel in patients with early triple-negative breast cancer

Triple-negative breast cancer (TNBC) is characterized by an aggressive behavior, highly sensitivity to chemotherapy, early recurrence, and also the absence of known targets for targeted therapies. TNBC is extremely impotant search for intensive regimens of neoadjuvant chemotherapy, because of insufficient effectiveness of conventional therapies. The aim of the study was to evaluate the efficacy and toxicity of cisplatin, doxorubicin, paclitaxel in patients with early breast cancer with triple-negative phenotype in preoperative mode. The study included 41 patients with early breast cancer, triple negative phenotype (T1-2 N0-1M0). Patients were treated with cisplatin 30 mg/m2 / IV., Doxorubicin 25 mg/m2 / IV., Paclitaxel 100 mg/m2 / IV. weekly for planned 8 weeks with G-CSF 300 mcg 2-4 days followed by surgery. The rate of objective response was 38/40 (95%) complete response - 12/40 (30%), partial regression - 26/40 (65%), stabilization - 2/40 (50%). 40 hftients were treated with surgery, 26/40 (65%) achieved a complete pathological regression. 2-year disease-free survival - 89.4%. 2-year overall survival - 95.1%. Combination of cisplatin, doxorubicin, paclitaxel, it proved its high efficacy in patients with early breast cancer with triple-negative phenotype, despite it' high toxicity.